非洲分子即时诊断检测(使用 NAAT)市场 – 行业趋势和 2028 年预测

请求目录 请求目录 与分析师交谈 与分析师交谈 立即购买 立即购买 购买前请咨询 提前咨询 免费样本报告 免费样本报告

非洲分子即时诊断检测(使用 NAAT)市场 – 行业趋势和 2028 年预测

  • Medical Devices
  • Published Report
  • Aug 2022
  • Country Level
  • 350 页面
  • 桌子數: 287
  • 图号: 42

非洲分子即时诊断检测(使用 NAAT)市场,按产品(仪器和消耗品及试剂)、适应症(呼吸道感染检测、性传播感染 (STI)检测、胃肠道感染检测等)、最终用户(实验室、医院、诊所、门诊中心、家庭护理、辅助生活设施等)、检测模式(基于处方的检测和 OTC 检测)、分销渠道(医院药房、零售药房和网上药房)– 行业趋势和预测到 2028 年。

非洲分子诊断即时检测(使用 NAAT)市场分析与洞察

非洲分子即时检测(使用 NAAT)市场预计将增长,因为医疗设施和基础设施的改善以及医院、实验室和诊所采用即时检测,这可以推动市场的发展。预计推动分子即时检测(使用 NAAT)市场增长的其他因素包括传染病患病率的上升。

其他因素,例如缺乏熟练的专业人员和定制分子即时检测(使用 NAAT)的高成本,阻碍了非洲分子即时检测(使用 NAAT)市场的增长。另一方面,医疗支出的增加和拥有发达医院的新兴国家为非洲分子即时检测(使用 NAAT)市场的增长提供了机会。

Data Bridge Market Research 分析,2021 年至 2028 年期间,非洲分子即时诊断(使用 NAAT)市场将以 5.8% 的复合年增长率增长。

报告指标

细节

预测期

2021 至 2028 年

基准年

2020

历史岁月

2019

定量单位

收入(百万美元),定价(美元)

涵盖的领域

按产品(仪器和耗材及试剂)、适应症(呼吸道感染检测、性传播感染 (STI) 检测、胃肠道感染检测等)、最终用户(实验室、医院、诊所、门诊中心、家庭护理、辅助生活设施等)、检测方式(处方检测和非处方药检测)、分销渠道(医院药房、零售药房和网上药房)

覆盖国家

南非、肯尼亚、尼日利亚和非洲其他地区

涵盖的市场参与者

雅培、F.Hoffmann-La Roche Ltd.、丹纳赫、赛默飞世尔科技公司、Sysmex Corporation、Meridian Bioscience、BD、Biomérieux Sa、Qiagen、Quidel Corporation、Bio-Rad Laboratories, Inc.、珀金埃尔默公司。

非洲分子诊断即时检测(使用 NAAT)市场定义

POCT 的特点是可以在患者附近进行检测,可以立即做出医疗决策,包括结果和监测。目前进入临床使用的 POCT 设备基于核酸扩增技术 (NAAT),本文将其定义为第二代设备。与第一代 POCT 相比,这些平台的灵敏度通常提高 60% 到 90%,并且需要便携式仪器,占地面积约为 30 厘米 x 30 厘米。这些仪器主要用于通过 NAAT 技术对各种疾病进行分子检测,例如 HIV、HPV 和呼吸系统疾病。NAAT 是核酸扩增技术,可通过检测病原体的 DNA 或 RNA 来识别病原体。

在全球大流行中,为了协同提高 NAAT 的灵敏度和 POCT 检测的易用性,设计了基于微型 NAAT 的 POCT 设备和检测,以更快地筛查和诊断 COVID-19,这也推动了市场的增长。

非洲分子诊断即时检测(使用 NAAT)市场动态

 本节旨在了解市场驱动因素、优势、机遇、限制和挑战。下面将详细讨论所有这些内容:

驱动程序

  • 增加慢性病的患病率

众所周知,健康衰退始于年龄的增长。随着慢性病的发病率随时间推移而增长,与发病率相关的因素也随之增加。肥胖/超重人口数量众多也增加了全球各个地区慢性病的患病率。HPV、STI 和 TB 等慢性病数量的增加,导致人们选择基于 NAAT 的即时检测和产品进行检测。因此,这可能会推动未来几年非洲分子即时检测(使用 NAAT)市场的增长。

  • 诊断率提高

随着癌症、贫血、二型糖尿病等慢性病的成功诊断率不断提高,医疗专业人员的素质不断提高,定期为专业人员提供检测培训,以提高该地区的诊断率。随着疾病负担的增加,诊断率也在提高。随着诊断技术的进步,接受诊断的人数也在增加。

  • 家庭护理检测的偏好上升

家庭医疗保健偏好使临床信息可以在正确的时间和地点获得。它还将有助于减少错误并在确保质量的情况下提高安全性。它们还可以在发生医疗紧急情况时为老年人提供帮助。医疗保健领域已经进行了许多战略性变革,以解决即时检测的好处。根据世界卫生组织 (WHO) 的数据,65 岁及以上人口的数量预计将从 2010 年的 5.24 亿增加到 2050 年的约 15 亿,其中发达国家占增长的大部分。

机会

  • 市场参与者采取的战略举措

全球慢性和非慢性疾病负担的增加,加上非洲和亚洲老年人口的增加,对开发新试剂盒和分子即时检测解决方案的需求越来越大,这些试剂盒和解决方案具有更好的功效和更少的耗时。为了在该地区提供诊断和筛查,市场参与者相互合作并达成协议,通过试剂盒和仪器为非洲人口提供优质护理。

  • 风险健康医疗支出

增加医疗支出和基础设施可以帮助患者轻松接受先进治疗,从而获得更好的诊断、手术和治疗,以快速康复。即时检测设备有利于检测各种疾病,并使用即时检测软件和解决方案支持治疗计划。医疗支出包括自付费用(人们支付医疗费用)、政府支出以及医疗保险和非政府组织活动等来源。

限制/挑战

  • 产品成本高

即时检测产品的开发过程需要相当可观的成本。由于需要确定概念,必须采购材料,并且必须考虑交货时间。此外,这个过程非常耗时,因为设备设计需要足够的时间才能完全成熟,然后才能投入市场使用。

  • 与实验室检测结果不一致

与实验室检测标准的结果相比,NAAT 检测结果有所不同。实验室检测更先进,遵循实验室检测的流程、协议和科学,并与准确分析、验证和记录效果所需的技术完全集成。然而,POCT/NAAT 无疑与缺乏精确的结果有关。分子 POCT 无法完成标准化,其他关键标准无法实现标准化和不同的基本标准。这对非洲分子即时检测市场来说是一个重大挑战。PoC 测试有时可能会提供错误的结果,并且测试结果存在差异。

后 COVID-19 对非洲分子即时诊断检测(使用 NAAT)市场的影响

COVID-19 严重影响了分子即时检测(使用 NAAT)市场。由于在线销售的不断增长和技术的进步,COVID-19 在更高水平上对分子即时检测(使用 NAAT)产品的价格和需求产生了积极影响。COVID-19 大流行的爆发对市场的增长产生了积极影响,因为对分子即时检测(使用 NAAT)的需求增加,尤其是在各家医院。由于 COVID-19 病例的激增仍在持续,大多数医院目前优先考虑 COVID-19 治疗,这也增加了分子即时检测(使用 NAAT)的使用。此外,许多国际政府和医疗保健组织都支持这些产品的供应,因为它们在危急情况下具有高度优先性。

最新动态

  • 2021 年 11 月,罗氏公司宣布,罗氏连续第十三年被评为道琼斯可持续发展指数中最具可持续性的三大医疗保健公司之一。这增加了预测期内的业务能力和业务扩张
  • 2021 年 10 月,赛默飞世尔科技公司获得 FDA 批准,用于 TaqMan COVId-19 检测 SARS-COV 分子检测。这增加了公司的产品组合,并在预测期内为公司收入做出了贡献

非洲分子诊断即时检测(使用 NAAT)市场范围

非洲分子即时检测(使用 NAAT)市场根据产品、适应症、最终用户、检测方式和分销渠道分为五个显著的细分市场。这些细分市场之间的增长将有助于分析行业中的市场增长细分市场,并为用户提供有价值的市场概览和市场洞察,帮助他们做出战略决策,确定核心市场应用。

产品

  • 仪器
  • 耗材和试剂

根据产品,非洲分子诊断即时检测(使用 NAAT)市场分为仪器、消耗品和试剂。

指征

  • 性传播感染 (STI) 检测
  • 呼吸道感染检测
  • 胃肠道感染检测
  • 其他的

根据适应症,非洲分子诊断即时检测(使用 NAAT)市场分为性传播感染 (STI) 检测、呼吸道感染检测、胃肠道感染检测等。

最终用户

  • 实验室
  • 医院
  • 诊所
  • 流动中心
  • 家庭护理
  • 辅助生活设施
  • 其他的

根据最终用户,非洲分子即时诊断(使用 NAAT)市场分为实验室、医院、诊所、门诊中心、家庭护理、辅助生活设施等。

测试方式

  • 基于处方的测试
  • OTC测试

根据测试模式,非洲分子护理点测试(使用 NAAT)市场分为基于处方的测试和 OTC 测试

分销渠道

  • 医院药房
  • 零售药店
  • 网上药店

分子诊断即时检测(使用 NAAT)市场

根据分销渠道,非洲分子诊断即时检测(使用 NAAT)市场分为医院药房、零售药房和在线药房。

非洲分子诊断即时检测(使用 NAAT)市场区域分析/见解

对非洲分子诊断即时检测(使用 NAAT)市场进行了分析,并根据产品、适应症、最终用户、检测模式和分销渠道提供了市场规模洞察和趋势。

非洲分子诊断即时检测(使用 NAAT)市场报告涵盖南非、肯尼亚、尼日利亚和非洲其他地区。

南非在非洲分子即时检测(使用 NAAT)市场占据主导地位,市场份额和市场收入的复合年增长率约为 6.1%。在预测期内,南非将继续保持主导地位。这是由于传染病和慢性病的发病率不断上升,以及医疗保健领域的技术进步不断加快。

竞争格局和非洲分子诊断即时检测(使用 NAAT)市场份额分析

非洲分子即时检测(使用 NAAT)市场竞争格局提供了有关竞争对手的详细信息。 其中包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、非洲业务、生产基地和设施、公司优势和劣势、产品发布、监管指南、品牌分析、产品批准、产品有效载荷、应用主导地位、技术生命线曲线。 以上数据点仅与专注于非洲分子即时检测(使用 NAAT)市场的公司有关。

非洲分子即时诊断检测(使用 NAAT)市场的一些主要参与者包括 Abbott、SD Biosensor、Thermo Fisher Scientific Inc., INC.、bioMérieux SA、Danaher、Hologic, Inc.、Seegene Inc.、Sysmex Corporation、F. Hoffmann-La Roche Ltd 等。


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

目录

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.7 MULTIVARIATE MODELLING

2.8 DISTRIBUTION CHANNEL LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 MARKET END USER COVERAGE GRID

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTERS FIVE FORCES

4.2 PESTEL ANALYSIS

4.3 ANNUAL TEST VOLUME: FOR ALL COUNTRIES

4.3.1 CEPHEID

4.3.2 THERMO FISHER SCIENTIFIC INC.

4.3.3 HOLOGIC, INC.

4.3.4 BD

4.3.5 F. HOFFMANN-LA ROCHE LTD

4.4 NUMBER OF POCT INSTRUMENTS INSTALLED IN EACH COUNTRY

4.5 PRICE PER POCT INSTRUMENT

4.5.1 NORTH AMERICA

4.5.2 EUROPE

4.5.3 SOUTH ASIA

4.5.4 SOUTH EAST ASIA

4.5.5 MIDDLE EAST

4.5.6 AFRICA

4.6 PRICE PER TEST

4.6.1 NORTH AMERICA

4.6.2 EUROPE

4.6.3 SOUTH ASIA

4.6.4 SOUTH EAST ASIA

4.6.5 MIDDLE EAST

4.6.6 AFRICA

4.7 MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS

4.8 MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI)

4.9 MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS

4.1 MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS

4.11 DISTRIBUTORS

4.11.1 NORTH AMERICA

4.11.2 EUROPE

4.11.3 SOUTH ASIA

4.11.4 SOUTH EAST ASIA

4.11.5 MIDDLE EAST

4.11.6 AFRICA

5 REGULATORY FRAMEWORK

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASING PREVALENCE OF CHRONIC DISEASES

6.1.2 IMPROVING DIAGNOSIS SEEKING RATE

6.1.3 RISING TECHNOLOGICAL ADVANCEMENTS

6.1.4 RISING GERIATRIC POPULATION ACROSS GLOBE

6.1.5 RISING PREFERENCE FOR HOMECARE TESTING

6.2 RESTRAINTS

6.2.1 PRODUCT RECALLS

6.2.2 HIGH COSTS OF PRODUCTS

6.2.3 NON-AVAILABILITY OF RELEVANT AND APPROPRIATE KITS

6.3 OPPORTUNITIES

6.3.1 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS

6.3.2 RISING HEALTHCARE EXPENDITURE

6.3.3 PANDEMIC OUTBREAK OF COVID-19

6.3.4 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE AND EARLY DIAGNOSIS

6.4 CHALLENGES

6.4.1 LACK OF ALIGNMENT WITH TEST RESULTS OBTAINED FROM LABORATORIES

6.4.2 LACK OF ACCESSIBILITY

7 IMPACT OF COVID-19 ON THE AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET

7.1 IMPACT ON PRICE

7.2 IMPACT ON DEMAND

7.3 IMPACT ON SUPPLY CHAIN

7.4 KEY INITIATIVES BY MARKET PLAYERS DURING THE COVID 19

7.5 CONCLUSION:

8 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT

8.1 OVERVIEW

8.2 CONSUMABLES & REAGENTS

8.3 INSTRUMENTS

8.3.1 MOBILE PLATFORM (SMALL & PORTABLE)

8.3.2 FACILITY-BASED PLATFORMS (LARGE POCT PLATFORM)

9 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION

9.1 OVERVIEW

9.2 RESPIRATORY INFECTIONS TESTING

9.2.1 COVID-19

9.2.2 FLU B

9.2.3 FLU A

9.2.4 RSV

9.2.5 TUBERCULOSIS

9.2.6 PNEUMONIA (PNEUMOCOCCAL PNEUMONIA)

9.2.7 OTHERS

9.3 SEXUALLY TRANSMITTED INFECTION (STI) TESTING

9.3.1 TV

9.3.2 CT

9.3.3 NG

9.3.4 HPV

9.3.5 HSV

9.3.6 MG

9.3.7 UU

9.3.8 MH

9.3.9 OTHERS

9.4 GASTROINTESTINAL TRACT INFECTIONS TESTING

9.4.1 GROUP B STREPTOCOCCUS

9.4.2 SHIGA TOXIN

9.4.3 H. PYLORI

9.5 OTHERS

10 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER

10.1 OVERVIEW

10.2 LABORATORIES

10.3 HOSPITAL

10.4 CLINICS

10.5 AMBULATORY CENTER

10.6 HOMECARE

10.7 ASSISTED LIVING FACILITIES

10.8 OTHERS

11 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING

11.1 OVERVIEW

11.2 PRESCRIPTION-BASED TESTING

11.3 OTC TESTING

12 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 DIRECT SALES

12.3 THIRD PARTY DISTRIBUTOR

12.4 ONLINE SALES

13 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION

13.1 AFRICA

13.1.1 SOUTH AFRICA

13.1.2 KENYA

13.1.3 NIGERIA

13.1.4 REST OF AFRICA

14 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: AFRICA

15 SWOT ANALYSIS

16 COMPANY PROFILE

16.1 DANAHER

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENTS

16.2 THERMO FISHER SCIENTIFIC INC.

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENTS

16.3 HOLOGIC, INC.

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENTS

16.4 BD

16.4.1 COMPANY SNAPSHOT

16.4.2 REVENUE ANALYSIS

16.4.3 COMPANY SHARE ANALYSIS

16.4.4 PRODUCT PORTFOLIO

16.4.5 RECENT DEVELOPMENTS

16.5 F.HOFFMANN-LA-ROCHE LTD.

16.5.1 COMPANY SNAPSHOT

16.5.2 REVENUE ANALYSIS

16.5.3 COMPANY SHARE ANALYSIS

16.5.4 PRODUCT PORTFOLIO

16.5.5 RECENT DEVELOPMENTS

16.6 ABBOTT

16.6.1 COMPANY SNAPSHOT

16.6.2 REVENUE ANALYSIS

16.6.3 PRODUCT PORTFOLIO

16.6.4 RECENT DEVELOPMENTS

16.7 BINX HEALTH, INC.

16.7.1 COMPANY SNAPSHOT

16.7.2 PRODUCT PORTFOLIO

16.7.3 RECENT DEVELOPMENT

16.8 BIOMERIEUX SA

16.8.1 COMPANY SNAPSHOT

16.8.2 REVENUE ANALYSIS

16.8.3 PRODUCT PORTFOLIO

16.8.4 RECENT DEVELOPMENT

16.9 BIO-RAD LABORATORIES, INC.

16.9.1 COMPANY SNAPSHOT

16.9.2 REVENUE ANALYSIS

16.9.3 PRODUCT PORTFOLIO

16.9.4 RECENT DEVELOPMENTS

16.1 CO-DIAGNOSTICS, INC.

16.10.1 COMPANY SNAPSHOT

16.10.2 REVENUE ANALYSIS

16.10.3 PRODUCT PORTFOLIO

16.10.4 RECENT DEVELOPMENTS

16.11 GENMARK DIAGNOSTICS, INC

16.11.1 COMPANY SNAPSHOT

16.11.2 REVENUE ANALYSIS

16.11.3 PRODUCT PORTFOLIO

16.11.4 RECENT DEVELOPMENT

16.12 GRIFOLS, S.A.

16.12.1 COMPANY SNAPSHOT

16.12.2 REVENUE ANALYSIS

16.12.3 PRODUCT PORTFOLIO

16.12.4 RECENT DEVELOPMENT

16.13 LUCIRA HEALTH INC.

16.13.1 COMPANY SNAPSHOT

16.13.2 PRODUCT PORTFOLIO

16.13.3 RECENT DEVELOPMENTS

16.14 MERIDIAN BIOSCIENCE

16.14.1 COMPANY SNAPSHOT

16.14.2 REVENUE ANALYSIS

16.14.3 PRODUCT PORTFOLIO

16.14.4 RECENT DEVELOPMENTS

16.15 OXFORD NANOPORE TECHNOLOGIES

16.15.1 COMPANY SNAPSHOT

16.15.2 PRODUCT PORTFOLIO

16.15.3 RECENT DEVELOPMENT

16.16 PERKIN ELMER INC.

16.16.1 COMPANY SNAPSHOT

16.16.2 REVENUE ANALYSIS

16.16.3 PRODUCT PORTFOLIO

16.16.4 RECENT DEVELOPMENT

16.17 QIAGEN

16.17.1 COMPANY SNAPSHOT

16.17.2 REVENUE ANALYSIS

16.17.3 PRODUCT PORTFOLIO

16.17.4 RECENT DEVELOPMENTS

16.18 QUANTUMDX GROUP LTD.

16.18.1 COMPANY SNAPSHOT

16.18.2 PRODUCT PORTFOLIO

16.18.3 RECENT DEVELOPMENTS

16.19 QUIDEL CORPORATION

16.19.1 COMPANY SNAPSHOT

16.19.2 REVENUE ANALYSIS

16.19.3 PRODUCT PORTFOLIO

16.19.4 RECENT DEVELOPMENT

16.2 RANDOX LABORATORIES LTD.

16.20.1 COMPANY SNAPSHOT

16.20.2 PRODUCT PORTFOLIO

16.20.3 RECENT DEVELOPMENTS

16.21 SD BIOSENSOR, INC.

16.21.1 COMPANY SNAPSHOT

16.21.2 PRODUCT PORTFOLIO

16.21.3 RECENT DEVELOPMENT

16.22 SEEGENE INC,

16.22.1 COMPANY SNAPSHOT

16.22.2 REVENUE ANALYSIS

16.22.3 PRODUCT PORTFOLIO

16.22.4 RECENT DEVELOPMENT

16.23 SEKISUI DIAGNOSTICS (A SUBSIDIARY OF SEKISUI MEDICAL)

16.23.1 COMPANY SNAPSHOT

16.23.2 PRODUCT PORTFOLIO

16.23.3 RECENT DEVELOPMENT

16.24 SYSMEX (A SUBSIDIARY OF SYSMEX CORPORATION

16.24.1 COMPANY SNAPSHOT

16.24.2 REVENUE ANALYSIS

16.24.3 PRODUCT PORTFOLIO

16.24.4 RECENT DEVELOPMENT

16.25 WONDFO

16.25.1 COMPANY SNAPSHOT

16.25.2 PRODUCT PORTFOLIO

16.25.3 RECENT DEVELOPMENT

17 QUESTIONNAIRE

18 RELATED REPORTS

表格列表

TABLE 1 CEPHEID: ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)

TABLE 2 THERMO FISHER SCIENTIFIC INC. : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)

TABLE 3 HOLOGIC, INC. : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)

TABLE 4 BD : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)

TABLE 5 F. HOFFMANN-LA ROCHE LTD : ANNUAL TEST VOLUME, FOR ALL COUNTRIES, 2020 (UNITS)

TABLE 6 NUMBER OF POCT INSTRUMENTS INSTALLED IN EACH COUNTRY, 2020 (UNITS)

TABLE 7 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS NORTH AMERICA (USD)

TABLE 8 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS NORTH AMERICA (USD)

TABLE 9 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS NORTH AMERICA (USD)

TABLE 10 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS NORTH AMERICA (USD)

TABLE 11 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS NORTH AMERICA (USD)

TABLE 12 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS NORTH AMERICA (USD)

TABLE 13 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS EUROPE (USD)

TABLE 14 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS EUROPE (USD)

TABLE 15 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS EUROPE (USD)

TABLE 16 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS EUROPE (USD)

TABLE 17 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS EUROPE (USD)

TABLE 18 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS EUROPE (USD)

TABLE 19 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS SOUTH ASIA (USD)

TABLE 20 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS SOUTH ASIA (USD)

TABLE 21 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS SOUTH ASIA (USD)

TABLE 22 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS SOUTH ASIA (USD)

TABLE 23 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS SOUTH ASIA (USD)

TABLE 24 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS SOUTH ASIA (USD)

TABLE 25 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS SOUTH EAST ASIA (USD)

TABLE 26 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS SOUTH EAST ASIA (USD)

TABLE 27 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS SOUTH EAST ASIA (USD)

TABLE 28 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS SOUTH EAST ASIA (USD)

TABLE 29 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS SOUTH EAST ASIA (USD)

TABLE 30 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS SOUTH EAST ASIA (USD)

TABLE 31 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS MIDDLE EAST (USD)

TABLE 32 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS MIDDLE EAST (USD)

TABLE 33 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS MIDDLE EAST (USD)

TABLE 34 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS MIDDLE EAST (USD)

TABLE 35 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS MIDDLE EAST (USD)

TABLE 36 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS MIDDLE EAST (USD)

TABLE 37 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS AFRICA (USD)

TABLE 38 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS AFRICA (USD)

TABLE 39 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER POCT INSTRUMENT ACROSS AFRICA (USD)

TABLE 40 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS AFRICA (USD)

TABLE 41 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS AFRICA (USD)

TABLE 42 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER POCT INSTRUMENT ACROSS AFRICA (USD)

TABLE 43 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 44 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 45 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 46 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 47 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 48 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 49 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS NORTH AMERICA (USD)

TABLE 50 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS NORTH AMERICA (USD)

TABLE 51 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS NORTH AMERICA (USD)

TABLE 52 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS NORTH AMERICA (USD)

TABLE 53 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS NORTH AMERICA (USD)

TABLE 54 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS NORTH AMERICA (USD)

TABLE 55 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 56 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 57 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 58 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 59 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 60 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS NORTH AMERICA (USD)

TABLE 61 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS NORTH AMERICA (USD)

TABLE 62 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS NORTH AMERICA (USD)

TABLE 63 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS NORTH AMERICA (USD)

TABLE 64 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS NORTH AMERICA (USD)

TABLE 65 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS NORTH AMERICA (USD)

TABLE 66 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS NORTH AMERICA (USD)

TABLE 67 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 68 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 69 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 70 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 71 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 72 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 73 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS EUROPE (USD)

TABLE 74 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS EUROPE (USD)

TABLE 75 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS EUROPE (USD)

TABLE 76 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS EUROPE (USD)

TABLE 77 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS EUROPE (USD)

TABLE 78 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS EUROPE (USD)

TABLE 79 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 80 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 81 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 82 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 83 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 84 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS EUROPE (USD)

TABLE 85 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS EUROPE (USD)

TABLE 86 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS EUROPE (USD)

TABLE 87 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS EUROPE (USD)

TABLE 88 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS EUROPE (USD)

TABLE 89 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS EUROPE (USD)

TABLE 90 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS EUROPE (USD)

TABLE 91 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 92 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 93 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 94 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 95 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 96 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 97 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH ASIA (USD)

TABLE 98 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH ASIA (USD)

TABLE 99 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH ASIA (USD)

TABLE 100 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH ASIA (USD)

TABLE 101 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH ASIA (USD)

TABLE 102 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH ASIA (USD)

TABLE 103 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 104 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 105 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 106 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 107 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 108 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH ASIA (USD)

TABLE 109 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH ASIA (USD)

TABLE 110 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH ASIA (USD)

TABLE 111 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH ASIA (USD)

TABLE 112 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH ASIA (USD)

TABLE 113 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH ASIA (USD)

TABLE 114 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH ASIA (USD)

TABLE 115 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 116 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 117 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 118 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 119 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 120 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 121 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 122 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 123 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 124 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 125 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 126 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 127 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 128 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 129 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 130 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 131 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 132 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 133 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 134 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 135 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 136 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 137 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 138 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS SOUTH EAST ASIA (USD)

TABLE 139 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 140 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 141 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 142 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 143 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 144 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 145 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS MIDDLE EAST (USD)

TABLE 146 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS MIDDLE EAST (USD)

TABLE 147 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS MIDDLE EAST (USD)

TABLE 148 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS MIDDLE EAST (USD)

TABLE 149 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS MIDDLE EAST (USD)

TABLE 150 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS MIDDLE EAST (USD)

TABLE 151 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 152 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 153 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 154 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 155 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 156 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS MIDDLE EAST (USD)

TABLE 157 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS MIDDLE EAST (USD)

TABLE 158 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS MIDDLE EAST (USD)

TABLE 159 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS MIDDLE EAST (USD)

TABLE 160 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS MIDDLE EAST (USD)

TABLE 161 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS MIDDLE EAST (USD)

TABLE 162 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS MIDDLE EAST (USD)

TABLE 163 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 164 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 165 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 166 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 167 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 168 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR RESPIRATORY INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 169 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS AFRICA (USD)

TABLE 170 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS AFRICA (USD)

TABLE 171 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS AFRICA (USD)

TABLE 172 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS AFRICA (USD)

TABLE 173 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS AFRICA (USD)

TABLE 174 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR SEXUALLY TRANSMITTED INFECTION (STI) TESTING ACROSS AFRICA (USD)

TABLE 175 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 176 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 177 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 178 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 179 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 180 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR GASTROINTESTINAL TRACT INFECTIONS TESTING ACROSS AFRICA (USD)

TABLE 181 LOW PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS AFRICA (USD)

TABLE 182 AVERAGE PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS AFRICA (USD)

TABLE 183 HIGH END PRICING (MANUFACTURER TO DISTRIBUTOR): PRICE PER TEST FOR OTHERS TESTING ACROSS AFRICA (USD)

TABLE 184 LOW PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS AFRICA (USD)

TABLE 185 AVERAGE PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS AFRICA (USD)

TABLE 186 HIGH END PRICING (DISTRIBUTOR TO LABS/HOSPITALS): PRICE PER TEST FOR OTHERS TESTING ACROSS AFRICA (USD)

TABLE 187 NORTH AMERICA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 188 NORTH AMERICA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 189 EUROPE MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 190 EUROPE MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 191 SOUTH ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 192 SOUTH ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 193 SOUTH EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 194 SOUTH EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 195 MIDDLE EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 196 MIDDLE EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 197 AFRICA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 198 AFRICA MARKET SHARE ANALYSIS BY COMPANIES FOR RESPIRATORY INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 199 NORTH AMERICA MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI) IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 200 EUROPE MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI) IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 201 SOUTH ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI) IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 202 SOUTH EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI) IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 203 MIDDLE EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI) IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 204 AFRICA MARKET SHARE ANALYSIS BY COMPANIES FOR SEXUALLY TRANSMITTED INFECTIONS (STI) IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 205 NORTH AMERICA MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 206 EUROPE MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 207 SOUTH ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 208 SOUTH EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 209 MIDDLE EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 210 AFRICA MARKET SHARE ANALYSIS BY COMPANIES FOR GASTROINTESTINAL INFECTIONS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 211 NORTH AMERICA MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 212 EUROPE MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 213 SOUTH ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 214 SOUTH EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 215 MIDDLE EAST ASIA MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 216 AFRICA MARKET SHARE ANALYSIS BY COMPANIES FOR OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, 2020-2028 (USD MILLION )

TABLE 217 DISTRIBUTORS ACROSS NORTH AMERICA

TABLE 218 DISTRIBUTORS ACROSS EUROPE

TABLE 219 DISTRIBUTORS ACROSS SOUTH ASIA

TABLE 220 DISTRIBUTORS ACROSS SOUTH EAST ASIA

TABLE 221 DISTRIBUTORS ACROSS MIDDLE EAST

TABLE 222 DISTRIBUTORS ACROSS AFRICA

TABLE 223 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 224 AFRICA CONSUMABLES & REAGENTS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 225 AFRICA PEDIATRIC IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 226 AFRICA INSTRUMENTS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 227 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 228 AFRICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 229 AFRICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 230 AFRICA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 231 AFRICA SEXUALLY TRANSMITTED IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 232 AFRICA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 233 AFRICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 234 AFRICA OTHERS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 235 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 236 AFRICA LABORATORIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 237 AFRICA HOSPITAL IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 238 AFRICA CLINICS IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 239 AFRICA AMBULATORY CENTER IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 240 AFRICA HOME CARE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 241 AFRICA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 242 AFRICA ASSISTED LIVING FACILITIES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 243 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 244 AFRICA PRESCRIPTION-BASED TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 245 AFRICA OTC TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 246 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 247 AFRICA DIRECT SALES IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 248 AFRICA THIRD PARTY DISTRIBUTOR IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 249 AFRICA ONLINE SALE IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY REGION, 2019-2028 (USD MILLION)

TABLE 250 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY COUNTRY, 2019-2028 (USD MILLION)

TABLE 251 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 252 AFRICA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 253 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 254 AFRICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 255 AFRICA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 256 AFRICA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)

TABLE 257 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 258 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 259 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 260 SOUTH AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 261 SOUTH AFRICA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 262 SOUTH AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 263 SOUTH AFRICA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 264 SOUTH AFRICA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 265 SOUTH AFRICAGASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)

TABLE 266 SOUTH AFRICAMOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 267 SOUTH AFRICAMOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 268 SOUTH AFRICAMOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 269 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 270 KENYA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 271 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 272 KENYA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 273 KENYA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 274 KENYA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)

TABLE 275 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 276 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 277 KENYA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 278 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 279 NIGERIA INSTRUMENT IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

TABLE 280 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 281 NIGERIA RESPIRATORY INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 282 NIGERIA SEXUALLY TRANSMITTED INFECTION (STI) TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY INDICATION, 2019-2028 (USD MILLION)

TABLE 283 NIGERIA GASTROINTESTINAL TRACT INFECTIONS TESTING IN MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, INDICATION, 2019-2028 (USD MILLION)

TABLE 284 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY END USER, 2019-2028 (USD MILLION)

TABLE 285 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY MODE OF TESTING, 2019-2028 (USD MILLION)

TABLE 286 NIGERIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)

TABLE 287 REST OF AFRICA & AFRCIA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET, BY PRODUCT, 2019-2028 (USD MILLION)

图片列表

FIGURE 1 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SEGMENTATION

FIGURE 2 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: DATA TRIANGULATION

FIGURE 3 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: DROC ANALYSIS

FIGURE 4 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: MULTIVARIATE MODELLING

FIGURE 8 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: DBMR MARKET POSITION GRID

FIGURE 9 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: END USER OVERAGE GRID

FIGURE 11 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SEGMENTATION

FIGURE 12 NORTH AMERICA IS EXPECTED TO DOMINATE THE AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET AND IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 13 INCREASING PREVALENCE OF CHRONIC DISEASE AND IMPROVING DIAGNOSIS SEEKING RATE ARE EXPECTED TO DRIVE THE AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 14 CONSUMABLES AND REAGENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET IN 2021 & 2028

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET

FIGURE 16 MEDICAL DEVICE SPENDING VS NATIONAL HEALTH EXPENDITURES, 2016

FIGURE 17 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, 2020

FIGURE 18 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, 2021-2028 (USD MILLION)

FIGURE 19 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, CAGR (2021-2028)

FIGURE 20 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT, LIFELINE CURVE

FIGURE 21 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, 2020

FIGURE 22 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, 2021-2028 (USD MILLION)

FIGURE 23 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, CAGR (2021-2028)

FIGURE 24 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY INDICATION, LIFELINE CURVE

FIGURE 25 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, 2020

FIGURE 26 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, 2021-2028 (USD MILLION)

FIGURE 27 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, CAGR (2021-2028)

FIGURE 28 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY END USER, LIFELINE CURVE

FIGURE 29 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, 2020

FIGURE 30 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, 2021-2028 (USD MILLION)

FIGURE 31 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, CAGR (2021-2028)

FIGURE 32 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY MODE OF TESTING, LIFELINE CURVE

FIGURE 33 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, 2020

FIGURE 34 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

FIGURE 35 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 36 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT)MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 37 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: SNAPSHOT (2020)

FIGURE 38 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020)

FIGURE 39 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2021 & 2028)

FIGURE 40 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY COUNTRY (2020 & 2028)

FIGURE 41 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: BY PRODUCT (2021-2028)

FIGURE 42 AFRICA MOLECULAR POINT OF CARE TESTING (USING NAAT) MARKET: COMPANY SHARE 2020 (%)

查看详细信息 Right Arrow

研究方法

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

可定制

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Africa Molecular Point of Care Testing (using NAAT) Market will grow at a CAGR of 5.8% by the forecast.
The major players operating in the Africa Molecular Point of Care Testing (using NAAT) Market are Abbott, F.Hoffmann-La Roche Ltd., Danaher, Thermo Fisher Scientific Inc, Sysmex Corporation, Meridian Bioscience, BD, Biomérieux Sa, Qiagen, Quidel Corporation, Bio-Rad Laboratories, Inc., PerkinElmer Inc.
The major countries covered in the Africa Molecular Point of Care Testing (using NAAT) Market are South Africa, Kenya, Nigeria and Rest of Africa.